09
Jun
2010
Cytheris, SA: Series D$14.3M
Posted in I - Series D, Q - 2Q10, R - INTERNATIONAL, X - HIV, X - Hepatitis C, X - Oncology
Cytheris (France) a clinical-stage biopharmaceutical immune modulation company focused on HIV, HCV and oncology, closed a $14.3M Series D financing. Participants include CDC Entreprises, Gestion, Caisse de dépôt et Placement du Québec, CDC Innovation, Crédit Agricole Private Equity and Forbion Capital Partners.
OnBioVC PARTNERS
-
